D91BB9Z
Brachytherapy Larynx to None with Iodine 125 (I-125), Low Dose Rate (LDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | 9 Ear, Nose, Mouth and Throat |
| Operation | 1 Brachytherapy |
| Body Part | B Larynx |
| Approach | B Low Dose Rate (LDR) |
| Device | 9 Iodine 125 (I-125) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy for ear, nose, mouth, and throat conditions involves placing a radioactive source directly into or next to a tumor, commonly in the oral cavity, tongue base, or nasopharynx. Because the source sits so close to the target tissue, it delivers a concentrated dose to the tumor while limiting exposure to surrounding healthy structures, which is valuable in a region crowded with nerves and tissue responsible for speech and swallowing.
The radioactive material may be temporary, removed after a set period, or permanently implanted depending on the isotope and clinical goal. This approach is often used alongside external beam radiation or surgery, particularly when a tumor recurs or when sparing normal tissue is a priority.
Anatomy & Axis Detail
Larynx
The larynx houses the vocal folds and the cartilaginous framework responsible for voice production, airway protection during swallowing, and respiration, making it a site where treatment decisions weigh oncologic control heavily against preservation of voice and airway function. Brachytherapy of the larynx is far less common than external beam approaches, typically reserved for recurrent or residual disease after prior radiation, and requires placement of interstitial catheters directly into laryngeal tissue, often under direct laryngoscopic guidance given the compact, cartilage-bound anatomy and proximity to the airway. The confined space and risk of airway compromise or cartilage necrosis demand careful source positioning, and records should capture the specific laryngeal subsite treated, such as the glottis or supraglottis, along with the number of catheters placed.
Modality Qualifier: Low Dose Rate (LDR)
Low Dose Rate (LDR) denotes brachytherapy using a source of lower activity that remains implanted or applied over an extended period, from many hours to a few days, exploiting continuous low-level irradiation for tumor control. This differs from High Dose Rate (HDR), which compresses the same general goal into brief, higher-intensity sessions, and LDR is often chosen for permanent seed implants such as certain prostate treatments.
Isotope: Iodine 125 (I-125)
Iodine-125 is a low-energy, low-dose-rate radioisotope most often loaded into small permanent seeds implanted directly into tissue, commonly for early-stage prostate cancer or ocular tumors via plaque brachytherapy. Its longer half-life (about 60 days) gives a slower, more protracted dose delivery than Pd-103 or Cs-131, which is the key distinction among the permanent-seed isotopes.
Coding & Documentation
Coders need documentation identifying the specific isotope or source used and confirming that the radioactive material was placed within or immediately adjacent to the target structure, not delivered from an external machine. The procedure note should specify whether the source is temporary or permanent, since this affects the qualifier assigned.